Ki-67 Labeling Index Predicts Tumor Progression Patterns and Survival in Patients with Atypical Meningiomas Following Stereotactic Radiosurgery

Overview

Journal J Neurooncol

Publisher Springer

Date 2024 Feb 18

PMID 38369575

Authors

Motoyuki Umekawa

Yuki Shinya

Hirotaka Hasegawa

Ramin A Morshed

Atsuto Katano

Aya Shinozaki-Ushiku

Nobuhito Saito

Affiliations

Soon will be listed here.

Abstract

Purpose: This study investigated whether Ki-67 labeling index (LI) correlated with clinical outcomes after SRS for atypical meningiomas.

Methods: This retrospective study examined 39 patients with atypical meningiomas who underwent SRS over a 10-year study period. Ki-67 LI was categorized into 3 groups: low (< 5%), intermediate (5%-10%), and high (> 10%). Local tumor control rates (LCRs), progression-free rates (PFRs), disease-specific survival (DSS) rates, and adverse radiation-induced events (AREs) were evaluated.

Results: The median follow-up periods were 26 months. SRS was performed at a median prescription dose of 18 Gy for tumors with a median Ki-67 LI of 9.6%. The 3-year LCRs were 100%, 74%, and 25% in the low, intermediate, and high LI groups, respectively (p = 0.011). The 3-year PFRs were 100%, 40%, and 0% in the low, intermediate, and high LI groups (p = 0.003). The 5-year DSS rates were 100%, 89%, and 50% in the low, intermediate, and high LI groups (p = 0.019). Multivariable Cox proportional hazard analysis showed a significant correlation of high LI with lower LCR (hazard ratio [HR], 3.92; 95% confidence interval [CI] 1.18-13.04, p = 0.026), lower PFR (HR 3.80; 95% CI 1.46-9.88, p = 0.006), and shorter DSS (HR 6.55; 95% CI 1.19-35.95, p = 0.031) compared with intermediate LI. The ARE rates were minimal (8%) in the entire group.

Conclusion: Patients with high Ki-67 LI showed significantly more tumor progression and tumor-related death. Ki-67 LI might offer valuable predictive insights for the post-SRS management of atypical meningiomas.

References

Goldbrunner R, Minniti G, Preusser M, Jenkinson M, Sallabanda K, Houdart E . EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016; 17(9):e383-91. DOI: 10.1016/S1470-2045(16)30321-7. View

DiBiase S, Kwok Y, Yovino S, Arena C, Naqvi S, Temple R . Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas. Int J Radiat Oncol Biol Phys. 2004; 60(5):1515-9. DOI: 10.1016/j.ijrobp.2004.05.073. View

Marchetti M, Pinzi V, Iezzoni C, Morlino S, Tramacere I, De Martin E . Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial. J Neurooncol. 2022; 157(3):397-403. PMC: 8979484. DOI: 10.1007/s11060-022-03978-w. View

Mair M, Berghoff A, Brastianos P, Preusser M . Emerging systemic treatment options in meningioma. J Neurooncol. 2022; 161(2):245-258. PMC: 9989003. DOI: 10.1007/s11060-022-04148-8. View

Nassiri F, Liu J, Patil V, Mamatjan Y, Wang J, Hugh-White R . A clinically applicable integrative molecular classification of meningiomas. Nature. 2021; 597(7874):119-125. PMC: 11604310. DOI: 10.1038/s41586-021-03850-3. View

Kowalchuk R, Shepard M, Sheehan K, Sheehan D, Faramand A, Niranjan A . Treatment of WHO Grade 2 Meningiomas With Stereotactic Radiosurgery: Identification of an Optimal Group for SRS Using RPA. Int J Radiat Oncol Biol Phys. 2021; 110(3):804-814. DOI: 10.1016/j.ijrobp.2021.01.048. View

Hasegawa H, Vakharia K, Link M, Stafford S, Brown P, Parney I . The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience. J Neurooncol. 2021; 155(3):335-342. DOI: 10.1007/s11060-021-03882-9. View

Sun S, Cai C, Murphy R, DeWees T, Dacey R, Grubb R . Radiation Therapy for Residual or Recurrent Atypical Meningioma: The Effects of Modality, Timing, and Tumor Pathology on Long-Term Outcomes. Neurosurgery. 2015; 79(1):23-32. DOI: 10.1227/NEU.0000000000001160. View

Kondziolka D, Patel A, Kano H, Flickinger J, Lunsford L . Long-term Outcomes After Gamma Knife Radiosurgery for Meningiomas. Am J Clin Oncol. 2014; 39(5):453-7. DOI: 10.1097/COC.0000000000000080. View

10.

Piper K, Yu S, Taghvaei M, Fernandez C, Mouchtouris N, Smit R . Radiation of meningioma dural tail may not improve tumor control rates. Front Surg. 2022; 9:908745. PMC: 9289604. DOI: 10.3389/fsurg.2022.908745. View

11.

Wang W, Lee C, Yang H, Liu K, Wu H, Shiau C . Gamma Knife Radiosurgery for Atypical and Anaplastic Meningiomas. World Neurosurg. 2015; 87:557-64. DOI: 10.1016/j.wneu.2015.10.021. View

12.

Shepard M, Xu Z, Kearns K, Li C, Chatrath A, Sheehan K . Stereotactic Radiosurgery for Atypical (World Health Organization II) and Anaplastic (World Health Organization III) Meningiomas: Results From a Multicenter, International Cohort Study. Neurosurgery. 2021; 88(5):980-988. DOI: 10.1093/neuros/nyaa553. View

13.

Unterberger A, Nguyen T, Duong C, Kondajji A, Kulinich D, Yang I . Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas. J Neurooncol. 2021; 152(2):205-216. DOI: 10.1007/s11060-020-03674-7. View

14.

Goldbrunner R, Stavrinou P, Jenkinson M, Sahm F, Mawrin C, Weber D . EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021; 23(11):1821-1834. PMC: 8563316. DOI: 10.1093/neuonc/noab150. View

15.

Kim M, Cho Y, Kim J, Kim C, Roh S, Kwon D . Role of gamma knife radiosurgery for recurrent or residual World Health Organization grade II and III intracranial meningiomas. Br J Neurosurg. 2020; 34(3):239-245. DOI: 10.1080/02688697.2020.1726285. View

16.

Piscevic I, Villa A, Milicevic M, Ilic R, Nikitovic M, Cavallo L . The Influence of Adjuvant Radiotherapy in Atypical and Anaplastic Meningiomas: A Series of 88 Patients in a Single Institution. World Neurosurg. 2015; 83(6):987-95. DOI: 10.1016/j.wneu.2015.02.021. View

17.

Jenkinson M, Javadpour M, Haylock B, Young B, Gillard H, Vinten J . The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials. 2015; 16:519. PMC: 4650615. DOI: 10.1186/s13063-015-1040-3. View

18.

Hardesty D, Wolf A, Brachman D, McBride H, Youssef E, Nakaji P . The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. J Neurosurg. 2013; 119(2):475-81. DOI: 10.3171/2012.12.JNS12414. View

19.

Champeaux C, Dunn L . World Health Organization grade II meningiomas. Acta Neurochir (Wien). 2016; 158(5):921-9. DOI: 10.1007/s00701-016-2771-y. View

20.

Ho D, Hsu C, Ting L, Chiang H . Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer. 2002; 94(5):1538-47. DOI: 10.1002/cncr.10351. View